跳至主要内容
临床试验/jRCT2032240323
jRCT2032240323招募中不适用

Safety and performance confirmation study with dMD-003 - Study to evaluate the safety and performance of dMD-003 in patients scheduled to undergo planned two-stage hepatectomy -

Mochida Pharmaceutical Co., Ltd.0 个研究点目标入组 15 人开始时间: 2024年11月19日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
15
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • (1) Patients with bilobar multiple liver metastasis from colon or rectal cancer who are eligible for a hepatectomy only if a planned two-stage hepatectomy is used.
  • (2) Patients scheduled to undergo a second-stage hepatectomy at 2 to 12 weeks after the date of the initial hepatectomy.
  • Other criteria.

排除标准

  • (1) Patients scheduled to undergo open resection along with the initial hepatectomy in the case of a concurrent primary colon or rectal tumor.
  • (2) Patients with a history of open surgery for a primary colon or rectal tumor.
  • (3) Patients who have previously undergone open surgery of the liver, bile duct, or upper abdomen.
  • Other criteria.

结局指标

主要结局

-

(1) Zuhlke classification (2) TORAD score

次要结局

未报告次要终点

研究者

相似试验